Monopar Therapeutics Inc.
MNPR
Positions held
Your positionsMNPR isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $563.69M | Enterprise value | $429.59M | Trailing P/E | — | Forward P/E | -43.84 |
| PEG | — | Price / book | 4.31 | Beta | 1.51 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -19.5% | ROA | -14.6% | Debt / equity | 0.00 |
| Current ratio | 33.56 | Free cash flow | -$6.10M | Analyst recommendation | strong_buy | Mean target | $129.92 |
| 52w high | $124.82 | 52w low | $50.07 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$5.3M | -$3.9M | -$5.2M | -$3.4M | -$2.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.6M | -$5.2M | -$6.2M | -$4.1M | -$3.2M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$13.7M | -$15.6M | -$8.4M | -$10.5M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$16.7M | -$16.2M | -$8.8M | -$10.5M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-05 · Monopar Therapeutics Insider Sold Shares Worth $659,387, According to a Recent SEC Filing
2026-08-13 · Sector Update: Healthcare Stocks Softer Late Afternoon
2026-08-13 · Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald
2026-08-13 · Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral From Overweight, Adjusts PT to $119 From $109
2026-08-12 · Monopar Therapeutics' Q2 Net Loss Widens
2026-08-12 · Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-07-22 · Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease
2026-07-22 · Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
Price (daily)
Full chart · RSI · MACD · patterns